Anastrozole is a potent and highly selective non-steroidal aromatase inhibitor. It inhibits the enzyme aromatase, which is responsible for converting androgens to estrogens. Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Anastrozole is the active ingredient of these drugs:
South Africa
Italy
Ireland
Spain
Ireland
Germany
South Africa
New Zealand
South Africa
South Africa
Finland
Tunisia
Tunisia
Germany
Australia
Austria
Brazil
Germany
Ecuador
Ecuador
New Zealand
Finland
Singapore
Singapore
Hong Kong
Italy
Brazil
Hong Kong Singapore
Brazil
Cyprus Hong Kong New Zealand Singapore
Australia
Australia Austria Brazil Canada Cyprus
Singapore
Poland
Tunisia
Estonia Lithuania
South Africa
South Africa
South Africa
Poland
South Africa
Italy
Hong Kong Singapore
Italy
South Africa
Italy
Italy
New Zealand
South Africa
Cyprus
Cyprus